2024-09-25 - Analysis Report
## AbbVie Inc. (ABBV) Stock Analysis Report

**1. Performance Comparison:**

AbbVie Inc. (ABBV) has outperformed the S&P 500 (VOO) with a cumulative return of 153.48% compared to VOO's 133.37%. This represents a 20.11% difference, which places it at the 61.29 percentile of its historical performance range (max: 56.45, min: -41.78).  

**Company Overview:** 

AbbVie Inc. is a global biopharmaceutical company that develops, manufactures, and markets a wide range of pharmaceutical products.

**2. Recent Price Movements:**

* **Closing Price:** $194.48
* **5-Day Moving Average:** $193.61
* **20-Day Moving Average:** $194.95
* **60-Day Moving Average:** $186.15

The stock price is slightly below its 20-day moving average, indicating a potential short-term pullback. However, it remains above the 60-day moving average, suggesting a longer-term bullish trend.

**3. Technical Indicators:**

* **RSI:** 44.34 -  This suggests the stock is neither overbought nor oversold, indicating a neutral sentiment.
* **PPO:** -0.35 - This indicates that the stock's price is currently lagging behind its moving average.
* **Delta_Previous_Relative_Divergence:** -7.86 - This indicates a recent short-term downward trend.
* **Expected_Return:** 7.263% -  Represents a potential 5-year expected return on investment.

**4. Recent Earnings & Outlook:**

| Date | EPS | Expected EPS |
|---|---|---|
| 2024-07-25 | 2.65 | 2.57 |
| 2024-04-26 | 2.31 | 2.26 |
| 2024-02-02 | 2.79 | 2.76 |
| 2023-10-27 | 2.95 | 2.86 |
| 2023-07-27 | 2.91 | 2.79 |

AbbVie has consistently exceeded analysts' expectations for EPS in recent quarters. The most recent earnings report for Q2 2024 showed EPS of $2.65, beating the estimated $2.57. This positive earnings trend suggests continued growth potential.

**5. News & Recent Issues:**

* **Recent Market Outlook:** 
    * AbbVie is a strong performer in the pharmaceutical sector, benefiting from its robust portfolio of blockbuster drugs.
    *  The company is facing challenges from biosimilar competition and the potential for patent expirations on some of its key products.
    *  Despite these challenges, AbbVie has a strong pipeline of new drugs under development, which could drive future growth. 
* **Analyst Opinions:** 
    * Analysts generally maintain a positive outlook on AbbVie, with many rating the stock as a "buy" or "hold."
    *  Concerns remain about the company's dependence on Humira, its top-selling drug, and the potential impact of biosimilar competition.
* **Performance Highlights:**
    * **FINBOLD:**  Reports AbbVie's strong financials and consistent dividend payouts, highlighting the company's commitment to shareholder returns.
    * **MarketBeat:**  Indicates a moderate buying sentiment with an average analyst rating of "Hold."

**6. Overall Analysis:**

AbbVie Inc. (ABBV) is a well-established pharmaceutical company with a solid track record of growth and profitability. While the stock has recently faced some headwinds due to competition and patent expirations, AbbVie's strong pipeline of new drugs and its consistent dividend payouts offer potential for future growth.  The stock currently shows a neutral to bullish technical outlook and has demonstrated strong earnings performance, surpassing analysts' expectations. However, investors should monitor the company's ability to navigate the challenges of biosimilar competition and patent expirations to ensure sustained long-term success. 

**7. Recommendation:** 

Based on the analysis, ABBV could be a good addition to a diversified portfolio for investors seeking exposure to the pharmaceutical sector. The stock's strong earnings performance and its potential for growth through its drug pipeline suggest it could generate attractive returns in the long term. However, investors should carefully consider the company's dependence on Humira and the potential impact of biosimilar competition before making any investment decisions.
